IQVIA, formerly known as Quintiles IMS, is a leading global provider of advanced analytics, technology solutions, and contract research services for the healthcare industry. Headquartered in the United States, IQVIA operates extensively across North America, Europe, and Asia, delivering insights that drive healthcare innovation. Founded in 2016 through the merger of Quintiles and IMS Health, IQVIA has quickly established itself as a pivotal player in the life sciences sector. The company offers a unique blend of data analytics, real-world evidence, and technology solutions, enabling clients to navigate the complexities of drug development and market access. With a strong market position, IQVIA is recognised for its comprehensive suite of services, including clinical trial management, commercialisation support, and data-driven insights. Its commitment to leveraging cutting-edge technology and deep industry expertise has earned it numerous accolades, solidifying its reputation as a trusted partner in the healthcare ecosystem.
How does Iqvia's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Research Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Iqvia's score of 77 is higher than 87% of the industry. This can give you a sense of how well the company is doing compared to its peers.
In 2023, IQVIA reported total greenhouse gas emissions of approximately 526.2 million kg CO2e. This includes Scope 1 emissions of about 8.2 million kg CO2e, Scope 2 emissions of approximately 28.7 million kg CO2e, and significant Scope 3 emissions totalling around 481.9 million kg CO2e. IQVIA has set ambitious climate commitments, aiming for a 55.1% reduction in absolute Scope 1 and 2 emissions by 2030, using a 2019 baseline. Additionally, the company targets a 90% reduction in total emissions across all scopes by 2050. These targets have been verified by the Science Based Targets initiative (SBTi) and align with the goal of achieving net-zero emissions by 2050. The near-term targets also include a specific commitment to reduce Scope 3 emissions from business travel by 55% per full-time equivalent (FTE) by 2030. Furthermore, IQVIA plans for 70% of its suppliers, based on emissions, to have science-based targets by 2027. These initiatives reflect IQVIA's commitment to sustainability and its proactive approach to addressing climate change within the pharmaceutical and biotechnology sector.
Access structured emissions data, company-specific emission factors, and source documents
| 2012 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|
| Scope 1 | 43,577,000 | 00,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 2 | 48,394,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | 45,222,000 | 00,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
Iqvia's Scope 3 emissions, which increased by 14% last year and increased by approximately 966% since 2012, demonstrating supply chain emissions tracking. The vast majority of their carbon footprint comes from suppliers and value chain emissions, representing the vast majority of total emissions under the GHG Protocol, with "Purchased Goods and Services" being the largest emissions source at 57% of Scope 3 emissions.
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Iqvia has established climate goals through participation in recognized frameworks and target-setting initiatives. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.


Common questions about Iqvia's sustainability data and climate commitments